

BioPharmica attempt to unlock HLS5 gene

18/01/06 By: Stephen Blaxhall



BIOPHARMICA

Cancer research company BioPharmica Ltd (BPH) today announce researchers from the Western Australian Institute for Medical Res (WAIMR) had discovered a link between the HLS5 gene and key a Huntington's disease and AIDS development. The company noted scientists at the institute were working on the role of HLS5 in can discovered that the HLS5 gene has potential involvement in sever regulatory processes within human cells.

The group added that processes have been shown to be important susceptibility and progression for diseases such as the neurodegenerative disease, Hunt and immune system regulation, including infectious diseases such as AIDS.

"HLS5 is now being developed as a key gene important in multiple disease processes, having multiple functional components," noted the company's statement to the ASX.

The Company has lodged international patent protection over the involvement of HLS5 in testing and treatment of these additional diseases, while further details on the Intellectual Property will be made available when the patents pass through the provisional application phase.

BioPharmica's MD Dr Sam Gallagher said that the company would continue to focus on diagnostic and therapeutic applications in cancer for HLS5 with WAIMR and noted that research conducted in animals at the Royal Perth Hospital campus of WAIMR has found that HLS5 has an anti-cancer effect.

"The study found that the introduction of HLS-5 reduced the formation of cancers in mic have also completed a pilot trial showing that the HLS5 gene was aberrant in the majori tissue samples from patients with cancer, consistent with its role as a tumour suppressc Gallagher

"The scientists at WAIMR have been exploring links and pathways that are now gatherin from International researchers," added the groups MD.

The company announced that rather than seek licensing and collaborations for HLS5 sol relation to cancer, BioPharmica would also actively seek potential opportunities in neuro and infectious diseases.

At 1030 AEDT **BioPharmica** were up 3c at 23c



BioPharmica attempt to unlock HLS5 gene

18/01/06 By: Stephen Blaxhall



Cancer research company BioPharmica Ltd (BPH) today announced that researchers from the Western Australian Institute for Medical Research (WAIMR) had discovered a link between the HLS5 gene and key aspects of Huntington's disease and AIDS development. The company noted that while scientists at the institute were working on the role of HLS5 in cancer, they discovered that the HLS5 gene has potential involvement in several key regulatory processes within human cells.

BIOPHARMICA The group added that processes have been shown to be important in susceptibility and progression for diseases such as the neurodegenerative disease, Huntington's and immune system regulation, including infectious diseases such as AIDS.

"HLS5 is now being developed as a key gene important in multiple disease processes, having multiple functional components," noted the company's statement to the ASX.

The Company has lodged international patent protection over the involvement of HLS5 in testing and treatment of these additional diseases, while further details on the Intellectual Property will be made available when the patents pass through the provisional application phase.

BioPharmica's MD Dr Sam Gallagher said that the company would continue to focus on diagnostic and therapeutic applications in cancer for HLS5 with WAIMR and noted that research conducted in animals at the Royal Perth Hospital campus of WAIMR has found that HLS5 has an anti-cancer effect.

"The study found that the introduction of HLS-5 reduced the formation of cancers in mice and we have also completed a pilot trial showing that the HLS5 gene was aberrant in the majority of tissue samples from patients with cancer, consistent with its role as a tumour suppressor" said Dr Gallagher.

"The scientists at WAIMR have been exploring links and pathways that are now gathering interest from international researchers," added the group's MD.

The company announced that rather than seek licensing and collaborations for HLS5 solely in relation to cancer, BioPharmica would also actively seek potential opportunities in neurodegenerative and infectious diseases.

At 1030 AEDT **BioPharmica** were **up 3c** at **23c**